Chemotherapy agents in human epidermal growth factor receptor 2-positive breast cancer: Time to step out of the limelight

Journal of Clinical Oncology

Volumn 29, Issue 3, 2011, Pages 251-253

  Lin, Nancy U ^a   Winer, Eric P ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANTINEOPLASTIC AGENT; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; NAVELBINE; NERATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

ALOPECIA; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; EDITORIAL; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; NAIL DISEASE; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DRUG SYNERGISM; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 79951996042     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.32.5290     Document Type: Editorial

References (22)

1. Bauer K, Parise C, Caggiano V: Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer 10:228, 2010
2. Kennecke H, Yerushalmi R, Woods R, et al: Metastatic behavior of breast cancer subtypes. J Clin Oncol 28:3271-3277, 2010
3. Pegram MD, Konecny GE, O'Callaghan C, et al: Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 96:739-749, 2004 (Pubitemid 38771819)
4. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001 (Pubitemid 32222155)
5. Marty M, Cognetti F, Maraninchi D, et al: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 23:4265-4274, 2005 (Pubitemid 46207001)
6. Andersson M, Lidbrink E, Bjerre K, et al: Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. J Clin Oncol 29:264-271, 2011
7. Burstein HJ, Keshaviah A, Baron AD, et al: Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: The trastuzumab and vinorelbine or taxane study. Cancer 110:965-972, 2007 (Pubitemid 47312860)
8. Burstein HJ, Harris LN, Marcom PK, et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895, 2003 (Pubitemid 46621838)
9. Chan A, Martin M, Untch M, et al: Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: An international phase II trial. Br J Cancer 95:788-793, 2006 (Pubitemid 44498091)
10. Bernardo G, Palumbo R, Bernardo A, et al: Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cancer. J Clin Oncol 22:59s, 2004 (suppl; abstr 731)
11. Jahanzeb M, Mortimer JE, Yunus F, et al: Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist 7:410-417, 2002 (Pubitemid 35266133)
12. Schilling G, Bruweleit M, Harbeck N, et al: Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy). Invest New Drugs 27:166-172, 2009
13. Dawood S, Broglio K, Buzdar AU, et al: Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: An institutional-based review. J Clin Oncol 28:92-98, 2010
14. Robert N, Leyland-Jones B, Asmar L, et al: Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24:2786-2792, 2006 (Pubitemid 46630577)
15. Chan A: A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 18:1152-1158, 2007
16. Pegram M, Forbes J, Pienkowski T, et al: BCIRG 007: First overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first-line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 25:34s, 2007 (suppl; abstr LBA 1008)
17. Infante JR, Yardley DA, Burris HA 3rd, et al: Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer 9:23-28, 2009
18. Harris LN, You F, Schnitt SJ, et al: Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 13:1198-1207, 2007 (Pubitemid 46424061)
19. Krop IE, Flores L, Tuck DP, et al: Phase II trial of preoperative vinorelbine/trastuzumab (VH) or docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer with analysis of resistance mechanisms. J Clin Oncol 28:79s, 2010 (suppl; abstr 549)
20. Esteva FJ, Guo H, Zhang S, et al: PTEN, PIK3CA, p-AKT, and p-p70S6K status: Association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:1647-1656, 2010
21. Scaltriti M, Rojo F, Ocaña A, et al: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638, 2007 (Pubitemid 47073544)
22. Scaltriti M, Chandarlapaty S, Prudkin L, et al: Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 16:2688-2695, 2010